26-week, international multicenter, open, non-randomized phase III clinical trial for evaluation of efficacy and safety of insulin glulysine (HME1964) injected subcutaneously in subjects with type 1 diabetes mellitus also using insulin glargine.
Phase of Trial: Phase III
Latest Information Update: 15 Mar 2010
At a glance
- Drugs Insulin glargine; Insulin glulisine
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 26 Oct 2007 New trial record.